hydroxychloroquine has been researched along with Lung Neoplasms in 25 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Lung Neoplasms: Tumors or cancer of the LUNG.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Here, we prepared R8-dGR peptide modified paclitaxel (PTX) and hydroxychloroquine (HCQ) co-loaded liposomes (PTX/HCQ-R8-dGR-Lip) for enhanced delivery by recognizing integrin αvβ3 receptors and neuropilin-1 receptors on B16F10 melanoma cells." | 7.88 | Dual receptor recognizing liposomes containing paclitaxel and hydroxychloroquine for primary and metastatic melanoma treatment via autophagy-dependent and independent pathways. ( He, Q; Li, M; Liu, J; Rao, J; Tang, X; Wan, D; Wang, X; Wang, Y; Wei, J; Xia, C; Yin, S; Zhang, Z, 2018) |
| " Here, we prepared R8-dGR peptide modified paclitaxel (PTX) and hydroxychloroquine (HCQ) co-loaded liposomes (PTX/HCQ-R8-dGR-Lip) for enhanced delivery by recognizing integrin αvβ3 receptors and neuropilin-1 receptors on B16F10 melanoma cells." | 3.88 | Dual receptor recognizing liposomes containing paclitaxel and hydroxychloroquine for primary and metastatic melanoma treatment via autophagy-dependent and independent pathways. ( He, Q; Li, M; Liu, J; Rao, J; Tang, X; Wan, D; Wang, X; Wang, Y; Wei, J; Xia, C; Yin, S; Zhang, Z, 2018) |
| "Hydroxychloroquine therapy was associated with a reduced risk (relative risk, 0." | 1.91 | Prevalence, incidence, and risk factors of malignancy in patients with rheumatoid arthritis: a nationwide cohort study from Korea. ( Ko, KM; Moon, SJ, 2023) |
| "Hydroxychloroquine (HCQ) has shown anti-tumor activity in a variety of tumor models." | 1.62 | Mass spectrometry imaging revealed alterations of lipid metabolites in multicellular tumor spheroids in response to hydroxychloroquine. ( Cai, Z; Chen, Y; Song, Y; Wang, J; Wang, T; Xie, P, 2021) |
| "It is known that patients with cancer are more susceptible to infection than individuals without cancer because of their systemic immunosuppressive state caused by the malignancy and anticancer treatments." | 1.56 | COVID-19 and lung cancer: risks, mechanisms and treatment interactions. ( Addeo, A; Friedlaender, A; Obeid, M, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (4.00) | 18.7374 |
| 1990's | 1 (4.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (36.00) | 24.3611 |
| 2020's | 14 (56.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y | 1 |
| Wang, T | 1 |
| Xie, P | 1 |
| Song, Y | 1 |
| Wang, J | 1 |
| Cai, Z | 1 |
| Shi, Y | 1 |
| Lin, G | 1 |
| Zheng, H | 1 |
| Mu, D | 1 |
| Chen, H | 2 |
| Lu, Z | 1 |
| He, P | 1 |
| Zhang, Y | 1 |
| Liu, C | 1 |
| Lin, Z | 1 |
| Liu, G | 1 |
| Wang, X | 2 |
| Shang, M | 1 |
| Sun, X | 1 |
| Guo, L | 1 |
| Xiao, S | 1 |
| Shi, D | 1 |
| Meng, D | 1 |
| Zhao, Y | 1 |
| Yang, L | 1 |
| Jiang, C | 1 |
| Li, J | 1 |
| Aggarwal, C | 1 |
| Maity, AP | 1 |
| Bauml, JM | 1 |
| Long, Q | 1 |
| Aleman, T | 1 |
| Ciunci, C | 1 |
| D'Avella, C | 1 |
| Volpe, M | 1 |
| Anderson, E | 1 |
| Jones, LM | 1 |
| Sun, L | 1 |
| Singh, AP | 1 |
| Marmarelis, ME | 1 |
| Cohen, RB | 1 |
| Langer, CJ | 1 |
| Amaravadi, R | 1 |
| Elshami, FI | 1 |
| Shereef, HA | 1 |
| El-Mehasseb, IM | 1 |
| Shaban, SY | 1 |
| van Eldik, R | 1 |
| Malhotra, J | 1 |
| Jabbour, S | 1 |
| Orlick, M | 1 |
| Riedlinger, G | 1 |
| Guo, Y | 1 |
| White, E | 1 |
| Aisner, J | 1 |
| Lyu, X | 1 |
| Zeng, L | 1 |
| Zhang, H | 1 |
| Ke, Y | 1 |
| Liu, X | 1 |
| Zhao, N | 1 |
| Yuan, J | 1 |
| Chen, G | 1 |
| Yang, S | 1 |
| Yekedüz, E | 1 |
| Dursun, B | 1 |
| Aydın, GÇ | 1 |
| Yazgan, SC | 1 |
| Öztürk, HH | 1 |
| Azap, A | 1 |
| Utkan, G | 1 |
| Ürün, Y | 1 |
| Addeo, A | 1 |
| Obeid, M | 1 |
| Friedlaender, A | 1 |
| Rogado, J | 2 |
| Pangua, C | 1 |
| Serrano-Montero, G | 1 |
| Obispo, B | 2 |
| Marino, AM | 1 |
| Pérez-Pérez, M | 1 |
| López-Alfonso, A | 1 |
| Gullón, P | 2 |
| Lara, MÁ | 2 |
| Luo, J | 1 |
| Rizvi, H | 1 |
| Preeshagul, IR | 1 |
| Egger, JV | 1 |
| Hoyos, D | 1 |
| Bandlamudi, C | 1 |
| McCarthy, CG | 1 |
| Falcon, CJ | 1 |
| Schoenfeld, AJ | 1 |
| Arbour, KC | 1 |
| Chaft, JE | 1 |
| Daly, RM | 1 |
| Drilon, A | 1 |
| Eng, J | 1 |
| Iqbal, A | 1 |
| Lai, WV | 1 |
| Li, BT | 1 |
| Lito, P | 1 |
| Namakydoust, A | 1 |
| Ng, K | 1 |
| Offin, M | 1 |
| Paik, PK | 1 |
| Riely, GJ | 1 |
| Rudin, CM | 1 |
| Yu, HA | 1 |
| Zauderer, MG | 1 |
| Donoghue, MTA | 1 |
| Łuksza, M | 1 |
| Greenbaum, BD | 1 |
| Kris, MG | 1 |
| Hellmann, MD | 1 |
| Montrone, M | 1 |
| Catino, A | 1 |
| Palmieri, VO | 1 |
| Longo, V | 1 |
| Galetta, D | 1 |
| Colombi, D | 1 |
| Bodini, FC | 1 |
| Morelli, N | 1 |
| Silva, M | 1 |
| Milanese, G | 1 |
| Cavanna, L | 1 |
| Michieletti, E | 1 |
| Serrano, G | 1 |
| Ko, KM | 1 |
| Moon, SJ | 1 |
| Yin, S | 1 |
| Xia, C | 1 |
| Wang, Y | 1 |
| Wan, D | 1 |
| Rao, J | 1 |
| Tang, X | 1 |
| Wei, J | 1 |
| Li, M | 2 |
| Zhang, Z | 1 |
| Liu, J | 1 |
| He, Q | 1 |
| Li, Y | 1 |
| Cao, F | 1 |
| Li, P | 1 |
| Yu, Y | 1 |
| Xiang, L | 1 |
| Xu, T | 1 |
| Lei, J | 1 |
| Tai, YY | 1 |
| Zhu, J | 1 |
| Yang, B | 1 |
| Jiang, Y | 1 |
| Zhang, X | 1 |
| Duo, L | 1 |
| Chen, P | 1 |
| Yu, X | 1 |
| O'Farrill, JS | 1 |
| Gordon, N | 1 |
| Leung, LS | 1 |
| Neal, JW | 2 |
| Wakelee, HA | 1 |
| Sequist, LV | 2 |
| Marmor, MF | 1 |
| Ruan, Y | 1 |
| Hu, K | 1 |
| You, L | 1 |
| Shou, J | 1 |
| Deng, D | 1 |
| Jiang, L | 1 |
| Jing, Z | 1 |
| Yao, J | 1 |
| Li, H | 1 |
| Xie, J | 1 |
| Wang, Z | 1 |
| Pan, Q | 1 |
| Pan, H | 1 |
| Huang, W | 1 |
| Han, W | 1 |
| Zhang, WC | 1 |
| Chin, TM | 1 |
| Yang, H | 1 |
| Nga, ME | 1 |
| Lunny, DP | 1 |
| Lim, EK | 1 |
| Sun, LL | 1 |
| Pang, YH | 1 |
| Leow, YN | 1 |
| Malusay, SR | 1 |
| Lim, PX | 1 |
| Lee, JZ | 1 |
| Tan, BJ | 1 |
| Shyh-Chang, N | 1 |
| Lim, EH | 1 |
| Lim, WT | 1 |
| Tan, DS | 1 |
| Tan, EH | 1 |
| Tai, BC | 1 |
| Soo, RA | 1 |
| Tam, WL | 1 |
| Lim, B | 1 |
| Goldberg, SB | 1 |
| Supko, JG | 1 |
| Muzikansky, A | 1 |
| Digumarthy, S | 1 |
| Fidias, P | 1 |
| Temel, JS | 1 |
| Heist, RS | 1 |
| Shaw, AT | 1 |
| McCarthy, PO | 1 |
| Lynch, TJ | 1 |
| Sharma, S | 1 |
| Settleman, JE | 1 |
| NAKAHARA, W | 1 |
| Brenner, S | 1 |
| Golan, H | 1 |
| Gat, A | 1 |
| Bialy-Golan, A | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase I Study of Hydroxychloroquine With or Without Erlotinib in Advanced NSCLC[NCT01026844] | Phase 1 | 27 participants (Actual) | Interventional | 2007-07-31 | Terminated (stopped due to slow enrollment) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
HCQ doses tested included 400mg, 600mg, 800mg, and 1000mg. Dose-limiting toxicities (DLTs) were defined as CTC of grade 2 or higher retinopathy or keratitis, or CTC of grade 3 or higher hematologic, skin, CNS, neuropathic, cardiac, respiratory, gastrointestinal, or renal AEs in the first cycle considered at least possibly related to HCQ. If a DLT was observed, an additional three patients were enrolled at that dose level. The maximum tolerated dose for HCQ in each arm would be defined as one dose level below that at which two or more of 6 patients experienced a DLT, or if no DLTs were observed, the highest tested dose. (NCT01026844)
Timeframe: 2 years
| Intervention | participants (Number) |
|---|---|
| Erlotinib Plus HCQ (Hydroxychloroquine) | 0 |
| HCQ (Hydroxychloroquine) | 0 |
PK parameter tested was dose normalized minimum steady state concentration (Cmin SS) of HCQ in micromolar per gram. Note this outcome was only analyzed for the first 21 patients enrolled, 13 on erlotinib/HCQ and 8 on HCQ arm. (NCT01026844)
Timeframe: 2 years
| Intervention | micromolar per gram (Mean) |
|---|---|
| Erlotinib Plus HCQ (Hydroxychloroquine) | 5.93 |
| HCQ (Hydroxychloroquine) | 9.40 |
Number of Response Evaluation Criteria in Solid Tumors (RECIST) responses divided by number of patients treated. Per RECIST version 1.0 complete response (CR) is defined as disappearance of all target lesions; Partial Response (PR) is defined as >=30% decrease in the sum of the longest diameter of target lesions. The objective tumor response rate is the CR + PR divided by the total number of patients (NCT01026844)
Timeframe: 2 years
| Intervention | percentage of patients (Number) |
|---|---|
| Erlotinib Plus HCQ (Hydroxychloroquine) | 5 |
| HCQ (Hydroxychloroquine) | 0 |
2 reviews available for hydroxychloroquine and Lung Neoplasms
| Article | Year |
|---|---|
Autophagy in osteosarcoma.
Topics: Animals; Antimetabolites, Antineoplastic; Autophagy; Bone and Bones; Bone Neoplasms; Cell Line, Tumo | 2014 |
Paraneoplastic subacute cutaneous lupus erythematosus: report of a case associated with cancer of the lung.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplasti | 1997 |
4 trials available for hydroxychloroquine and Lung Neoplasms
| Article | Year |
|---|---|
A Phase II Open-Label Trial of Binimetinib and Hydroxychloroquine in Patients With Advanced KRAS-Mutant Non-Small Cell Lung Cancer.
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Female; Humans; Hydr | 2023 |
Phase Ib/II study of hydroxychloroquine in combination with chemotherapy in patients with metastatic non-small cell lung cancer (NSCLC).
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antirheumatic Ag | 2019 |
Rapid Onset of Retinal Toxicity From High-Dose Hydroxychloroquine Given for Cancer Therapy.
Topics: Aged; Antineoplastic Agents; Antirheumatic Agents; Carcinoma, Non-Small-Cell Lung; Drug Therapy, Com | 2015 |
A phase I study of erlotinib and hydroxychloroquine in advanced non-small-cell lung cancer.
Topics: Adenocarcinoma; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Ce | 2012 |
19 other studies available for hydroxychloroquine and Lung Neoplasms
| Article | Year |
|---|---|
Mass spectrometry imaging revealed alterations of lipid metabolites in multicellular tumor spheroids in response to hydroxychloroquine.
Topics: Chromatography, Liquid; Humans; Hydroxychloroquine; Lung Neoplasms; Phosphatidylcholines; Spheroids, | 2021 |
Biomimetic nanoparticles blocking autophagy for enhanced chemotherapy and metastasis inhibition via reversing focal adhesion disassembly.
Topics: Animals; Antineoplastic Agents; Autophagy; Biomimetic Materials; Cadherins; Cell Line, Tumor; Cell M | 2021 |
Dual-responsive nanodroplets combined with ultrasound-targeted microbubble destruction suppress tumor growth and metastasis via autophagy blockade.
Topics: Autophagy; Cell Line, Tumor; Drug Liberation; Humans; Hydroxychloroquine; Lung Neoplasms; Microbubbl | 2022 |
Hydroxychloroquine-Loaded Chitosan Nanoparticles Induce Anticancer Activity in A549 Lung Cancer Cells: Design, BSA Binding, Molecular Docking, Mechanistic, and Biological Evaluation.
Topics: Anti-Bacterial Agents; Chitosan; Drug Liberation; Gram-Negative Bacteria; Gram-Positive Bacteria; Hu | 2023 |
Hydroxychloroquine suppresses lung tumorigenesis via inducing FoxO3a nuclear translocation through STAT3 inactivation.
Topics: A549 Cells; Active Transport, Cell Nucleus; Adenocarcinoma; Animals; Antineoplastic Agents; Apoptosi | 2020 |
Clinical course of COVID-19 infection in elderly patient with melanoma on nivolumab.
Topics: Aged; Antineoplastic Agents, Immunological; Antiviral Agents; Azithromycin; Betacoronavirus; Coronav | 2020 |
COVID-19 and lung cancer: risks, mechanisms and treatment interactions.
Topics: Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; Clinical Trials as Topic; Coro | 2020 |
Covid-19 and lung cancer: A greater fatality rate?
Topics: Aged; Aged, 80 and over; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; Cross Infe | 2020 |
COVID-19 in patients with lung cancer.
Topics: Adult; Aged; Aged, 80 and over; B7-H1 Antigen; Betacoronavirus; Coronavirus Infections; COVID-19; CO | 2020 |
Favourable outcome of coronavirus disease 2019 in a patient with anaplastic lymphoma kinase-positive non-small-cell lung cancer receiving alectinib.
Topics: Aged; Anaplastic Lymphoma Kinase; Anti-HIV Agents; Betacoronavirus; Carbazoles; Carcinoma, Non-Small | 2020 |
COVID-19 outbreak in Italy: Clinical-radiological presentation and outcome in three oncologic patients.
Topics: Aged; Anti-Bacterial Agents; Antiviral Agents; Betacoronavirus; Carcinoma, Squamous Cell; Coronaviru | 2021 |
Prolonged SARS-CoV-2 viral shedding in patients with solid tumours and associated factors.
Topics: Adenosine Monophosphate; Aged; Alanine; Antineoplastic Agents; Antiviral Agents; Breast Neoplasms; C | 2021 |
Prevalence, incidence, and risk factors of malignancy in patients with rheumatoid arthritis: a nationwide cohort study from Korea.
Topics: Arthritis, Rheumatoid; Cohort Studies; Female; Humans; Hydroxychloroquine; Incidence; Lung Neoplasms | 2023 |
Dual receptor recognizing liposomes containing paclitaxel and hydroxychloroquine for primary and metastatic melanoma treatment via autophagy-dependent and independent pathways.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Cell Line | 2018 |
Hydroxychloroquine induced lung cancer suppression by enhancing chemo-sensitization and promoting the transition of M2-TAMs to M1-like macrophages.
Topics: A549 Cells; Animals; ATP Binding Cassette Transporter, Subfamily B; Carcinoma, Non-Small-Cell Lung; | 2018 |
Autophagy inhibition enhances isorhamnetin‑induced mitochondria‑dependent apoptosis in non‑small cell lung cancer cells.
Topics: Adenine; Animals; Antineoplastic Agents, Phytogenic; Apoptosis; Autophagy; Carcinoma, Non-Small-Cell | 2015 |
Crizotinib induces autophagy through inhibition of the STAT3 pathway in multiple lung cancer cell lines.
Topics: Animals; Autophagy; Cell Line, Tumor; Cell Survival; Crizotinib; Drug Synergism; Eukaryotic Initiati | 2015 |
Tumour-initiating cell-specific miR-1246 and miR-1290 expression converge to promote non-small cell lung cancer progression.
Topics: A549 Cells; Animals; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; | 2016 |
NEWER STUDIES ON THE CARCINOGENIC ACTION OF QUINOLINE N-OXIDE DERIVATIVES.
Topics: Carcinogens; Hydroxychloroquine; Lung Neoplasms; Oxides; Quinolines; Rats; Research; Toxicology | 1964 |